Search Results - "Urologic Oncology: Seminars and Original Investigations"

Urinary biomarkers in bladder cancer: A review of the current landscape and future directions by Ng, Kenrick, Stenzl, Arnulf, Sharma, Anand, Vasdev, Nikhil

“…This narrative review aims to describe established and emerging urinary biomarkers in the diagnosis and surveillance of non-muscle invasive bladder cancer. It…”
Get full text

Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database by Singla, Nirmish, Hutchinson, Ryan C., Ghandour, Rashed A., Freifeld, Yuval, Fang, Dong, Sagalowsky, Arthur I., Lotan, Yair, Bagrodia, Aditya, Margulis, Vitaly, Hammers, Hans J., Woldu, Solomon L.

“…•Using the NCDB, patients undergoing CN with modern IO for mRCC exhibited better OS than those treated with IO alone.•CN after prior IO is safe with…”
Get full text

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer by Yafi, Faysal A., M.D, Brimo, Fadi, M.D, Steinberg, Jordan, M.D, Aprikian, Armen G., M.D, Tanguay, Simon, M.D, Kassouf, Wassim, M.D., F.R.C.S.(C)

“…Abstract Introduction Although urinary cytology (C) is the most widely used noninvasive test for the detection and surveillance of bladder cancer (BC), it has…”
Get full text

A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer by Hanke, Merle, Ph.D, Hoefig, Kai, Ph.D, Merz, Hartmut, M.D, Feller, Alfred C., M.D, Kausch, Ingo, Ph.D, Jocham, Dieter, M.D, Warnecke, Jens M., Ph.D, Sczakiel, Georg, Ph.D

“…Abstract Objectives MicroRNAs have been shown to be related to specific types of malignant cell growth. In case of urothelial bladder cancer (BCa), novel…”
Get full text

Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer by Ferro, Matteo, Barone, Biagio, Crocetto, Felice, Lucarelli, Giuseppe, Busetto, Gian Maria, Del Giudice, Francesco, Maggi, Martina, Crocerossa, Fabio, Cantiello, Francesco, Damiano, Rocco, Borghesi, Marco, Bove, Pier Luigi, Papalia, Rocco, Mari, Andrea, Luzzago, Stefano, Soria, Francesco, Marchioni, Michele, La Civita, Evelina, Terracciano, Daniela, Mistretta, Francesco Alessandro, Piccinelli, Mattia, Marmiroli, Andrea, Russo, Giorgio Ivan, Schips, Luigi, Hurle, Rodolfo, Contieri, Roberto, Perdonà, Sisto, Del Prete, Paola, Mirone, Vincenzo, Tataru, Octavian Sabin, Musi, Gennaro, Montanari, Emanuele, de Cobelli, Ottavio, Vartolomei, Mihai Dorin

“…•High-grade non-muscle invasive bladder cancer treated with transurethral resection of bladder tumor (TURB) plus bacillus of Calmette-Guerin (BCG).•Up to 40%…”
Get full text

Metastatic renal cell carcinoma: Patterns and predictors of metastases—A contemporary population-based series by Chandrasekar, Thenappan, Klaassen, Zachary, Goldberg, Hanan, Kulkarni, Girish S., Hamilton, Robert J., Fleshner, Neil E.

“…To assess the patterns and predictors of metastatic disease in renal cell carcinoma (RCC) at the time of diagnosis in a contemporary series. The Surveillance,…”
Get full text

Mental health implications in bladder cancer patients: A review by Pham, Hannah, Torres, Harrison, Sharma, Pranav

“…•Mental health is understudied in the diagnosis and treatment of bladder cancer.•Psychological illness, such as depression and anxiety, coexists with bladder…”
Get full text

The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor by Cui, Zilian, M.D., Ph.D, Ren, Shancheng, M.D., Ph.D, Lu, Ji, M.S, Wang, Fubo, M.S, Xu, Weidong, M.S, Sun, Yi, M.S, Wei, Min, M.S, Chen, Junyi, Ph.D, Gao, Xu, M.D., Ph.D, Xu, Chuanliang, M.D., Ph.D, Mao, Jian-Hua, Ph.D, Sun, Yinghao, M.D., Ph.D

“…Abstract Objective Emerging evidences implicate long noncoding RNAs (lncRNAs) are deregulated in cancer development. The purpose of the current study is to…”
Get full text

Intratumor heterogeneity in prostate cancer by Yadav, Shalini S., Stockert, Jennifer A., Hackert, Victoria, Yadav, Kamlesh K., Tewari, Ashutosh K.

“…Prostate cancer (PCa) has long been thought of as a disease with a heterogeneous phenotype. It can manifest in men as benign growths that can be safely watched…”
Get full text

The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients by Ogihara, Koichiro, Kikuchi, Eiji, Shigeta, Keisuke, Okabe, Takashi, Hattori, Seiya, Yamashita, Ryo, Yoshimine, Shunsuke, Shirotake, Suguru, Nakazawa, Ryuto, Matsumoto, Kazuhiro, Mizuno, Ryuichi, Hara, Satoshi, Oyama, Masafumi, Masuda, Takeshi, Niwakawa, Masashi, Oya, Mototsugu

“…•We focused on platinum-resistant urothelial carcinoma patients who received pembrolizumab treatment.•Pretreatment neutrophil-to-lymphocyte ratio levels were…”
Get full text

Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis by Berlin, Alejandro, Castro-Mesta, Julio F., Rodriguez-Romo, Laura, Hernandez-Barajas, David, González-Guerrero, Juan F., Rodríguez-Fernández, Iván A., González-Conchas, Galileo, Verdines-Perez, Adrian, Vera-Badillo, Francisco E.

“…Ki-67 for quantifying tumor proliferation is widely used. In localized prostate cancer (PCa), despite a suggested predictive role of Ki-67 for outcomes after…”
Get full text

Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma by Singla, Nirmish, Elias, Roy, Ghandour, Rashed A., Freifeld, Yuval, Bowman, Isaac A., Rapoport, Leonid, Enikeev, Mikhail, Lohrey, Jay, Woldu, Solomon L., Gahan, Jeffrey C., Bagrodia, Aditya, Brugarolas, James, Hammers, Hans J., Margulis, Vitaly

“…•Nephrectomy after immune checkpoint inhibition (ICI) is safe and technically feasible.•Surgical outcomes and pathologic response after ICI are favorable for…”
Get full text

Natural history of surgically treated high-risk prostate cancer by Briganti, Alberto, M.D, Karnes, Robert Jeffrey, M.D, Gandaglia, Giorgio, M.D, Spahn, Martin, M.D, Gontero, Paolo, M.D, Tosco, Lorenzo, M.D, Kneitz, Burkhard, M.D, Chun, Felix K.H., M.D, Zaffuto, Emanuele, M.D, Sun, Maxine, M.D, Graefen, Markus, M.D, Marchioro, Giansilvio, M.D, Frohneberg, Detlef, M.D, Giona, Simone, M.D, Karakiewicz, Pierre I., M.D, Van Poppel, Hein, M.D, Montorsi, Francesco, M.D, Joniau, Steven, M.D

“…Abstract Background No data exist on the patterns of biochemical recurrence (BCR) and their effect on survival in patients with high-risk prostate cancer (PCa)…”
Get full text

Frailty as a predictor of complications after radical cystectomy: A prospective study of various preoperative assessments by Burg, Madeleine L., Clifford, Thomas G., Bazargani, Soroush T., Lin-Brande, Michael, Miranda, Gus, Cai, Jie, Schuckman, Anne K., Djaladat, Hooman, Daneshmand, Siamak

“…•Prospective studies examining frailty and radical cystectomy (RC) are lacking.•We preoperatively assessed 123 patients undergoing RC and recorded…”
Get full text

Comparative effectiveness of robot-assisted vs. open radical cystectomy by Hanna, Nawar, Leow, Jeffrey J., Sun, Maxine, Friedlander, David F., Seisen, Thomas, Abdollah, Firas, Lipsitz, Stuart R., Menon, Mani, Kibel, Adam S., Bellmunt, Joaquim, Choueiri, Toni K., Trinh, Quoc-Dien

“…Over the past decade, robot-assisted radical cystectomy (RARC) has gained traction as an alternative to the conventional open approach open radical cystectomy…”
Get full text

Role of miRNAs in prostate cancer: Do we really know everything? by Cochetti, Giovanni, Rossi de Vermandois, Jacopo Adolfo, Maulà, Vincenza, Giulietti, Matteo, Cecati, Monia, Del Zingaro, Michele, Cagnani, Rosy, Suvieri, Chiara, Paladini, Alessio, Mearini, Ettore

“…•MiRNAs are involved in key steps of prostate cancer development and progression.•MiRNAs act as oncogenic or oncosuppressor factor in cancerogenesis.•MiRNAs as…”
Get full text

Impact of hospital case volume on testicular cancer outcomes and practice patterns by Woldu, Solomon L., Matulay, Justin T., Clinton, Timothy N., Singla, Nirmish, Krabbe, Laura-Maria, Hutchinson, Ryan C., Sagalowsky, Arthur, Lotan, Yair, Margulis, Vitaly, Bagrodia, Aditya

“…Given the rarity of testicular germ cell tumors (TGCTs) and the complex aspects of management, we evaluate the effect of hospital TGCT case volume on overall…”
Get full text

Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity–focused ultrasound focal therapy for localized prostate cancer by Dickinson, Louise, M.B.B.S., Ph.D, Ahmed, Hashim U., Ph.D., F.R.C.S. (Urol), Hindley, Richard G., F.R.C.S. (Urol), McCartan, Neil, M.Sc, Freeman, Alex, F.R.C. Path, Allen, Clare, F.R.C.R, Emberton, Mark, M.D., F.R.C.S. (Urol), Kirkham, Alex P., F.R.C.R

“…Abstract Introduction Focal therapy for localized prostate cancer has the potential for oncological control without the side effects of radical therapies…”
Get full text

High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer by Li, Qiaqia, Li, Chao, Chen, Jinbo, Liu, Peihua, Cui, Yu, Zhou, Xinyi, Li, Huihuang, Zu, Xiongbing

“…To explore the function of NORAD in bladder cancer (BC), and to verify whether NORAD could be used as a biomarker to determine preoperative presence of…”
Get full text

The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review by Boissier, Romain, M.D, Campagna, Jennifer, M.D, Branger, Nicolas, M.D, Karsenty, Gilles, M.D., Ph.D, Lechevallier, Eric, M.D., Ph.D

“…Abstract Background The neutrophil-lymphocyte ratio (NLR) is a biological marker of inflammation with a significant prognostic value in the field of oncology…”
Get full text